There is no clinical penalty for staying at a lower dose longer
You need the one that feels most possible right now
Results of the current studies support the hypothesis that the combination of amylin with GLP-1-based pharmacotherapy, in particular a stepwise-administration of sCT and liraglutide, results in a greater suppression of feeding, body weight and adiposity compared to administration of amylin or GLP-1 analogs alone
However, it can also lead to symptoms like early satiety, bloating, constipation, or nausea
GLP-1 RAs = glucagon-like peptide-1 receptor agonists GLP-1/GIPRAs = dual glucagon-like peptide-1 / glucose-dependent insulinotrophic peptide receptor co-agonists ANZCAs latest clinical practice recommendations were updated and released in April 2025 here are the key changes you need to know
ZhangRMiaoQWZhuCXZhaoYLiuLYangJet al